Literature DB >> 18951834

Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Yulia Nefedova1, Dmitry Gabrilovich.   

Abstract

Activation of Notch signaling has been implicated in pathogenesis of various hematologic tumors including leukemias, lymphomas, and multiple myeloma. Pre-clinical studies have suggested that inhibition of Notch could be an attractive new approach to treatment of hematologic malignancies. This review discusses most recent findings in the field and potential role of Notch signaling as a therapeutic target focusing on the effects of gamma-secretase inhibitors.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18951834      PMCID： PMC2731237          DOI： 10.1016/j.drup.2008.09.002

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN： 1368-7646            Impact factor:   18.500


  60 in total

1.  Nuclear magnetic resonance structure of a prototype Lin12-Notch repeat module from human Notch1.

Authors:  Didem Vardar; Christopher L North; Cheryll Sanchez-Irizarry; Jon C Aster; Stephen C Blacklow
Journal:  Biochemistry       Date:  2003-06-17       Impact factor: 3.162

Review 2.  Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration.

Authors:  Dennis Selkoe; Raphael Kopan
Journal:  Annu Rev Neurosci       Date:  2003-04-18       Impact factor: 12.449

3.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.

Authors:  Yulia Nefedova; Pingyan Cheng; Melissa Alsina; William S Dalton; Dmitry I Gabrilovich
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

4.  Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells.

Authors:  Franziska Jundt; Kristina Schulze Pröbsting; Ioannis Anagnostopoulos; Gwendolin Muehlinghaus; Manik Chatterjee; Stephan Mathas; Ralf C Bargou; Rudolf Manz; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

5.  CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.

Authors:  T Palomero; K C Barnes; P J Real; J L Glade Bender; M L Sulis; V V Murty; A I Colovai; M Balbin; A A Ferrando
Journal:  Leukemia       Date:  2006-05-11       Impact factor: 11.528

6.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.

Authors:  Franziska Jundt; Ioannis Anagnostopoulos; Reinhold Förster; Stephan Mathas; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 7.  CSL-independent Notch signalling: a checkpoint in cell fate decisions during development?

Authors:  Alfonso Martinez Arias; Vincent Zecchini; Keith Brennan
Journal:  Curr Opin Genet Dev       Date:  2002-10       Impact factor: 5.578

Review 8.  HES and HERP families: multiple effectors of the Notch signaling pathway.

Authors:  Tatsuya Iso; Larry Kedes; Yasuo Hamamori
Journal:  J Cell Physiol       Date:  2003-03       Impact factor: 6.384

9.  Notch1 enhances B-cell receptor-induced apoptosis in mature activated B cells without affecting cell cycle progression and surface IgM expression.

Authors:  S Romer; U Saunders; H-M Jäck; B M Jehn
Journal:  Cell Death Differ       Date:  2003-07       Impact factor: 15.828

10.  Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

Authors:  Gwendolyn T Wong; Denise Manfra; Frederique M Poulet; Qi Zhang; Hubert Josien; Thomas Bara; Laura Engstrom; Maria Pinzon-Ortiz; Jay S Fine; Hu-Jung J Lee; Lili Zhang; Guy A Higgins; Eric M Parker
Journal:  J Biol Chem       Date:  2004-01-06       Impact factor: 5.157
View more
  14 in total

1.  Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.

Authors:  Agnieszka Martowicz; Johann Kern; Eberhard Gunsilius; Gerold Untergasser
Journal:  J Vis Exp       Date:  2015-05-01       Impact factor: 1.355

Review 2.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

Review 3.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

4.  Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.

Authors:  Feng Chen; Alexandra Pisklakova; Ming Li; Rachid Baz; Daniel M Sullivan; Yulia Nefedova
Journal:  Cell Oncol (Dordr)       Date:  2011-10-01       Impact factor: 6.730

5.  Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

Authors:  Ming Li; Feng Chen; Nicholas Clifton; Daniel M Sullivan; William S Dalton; Dmitry I Gabrilovich; Yulia Nefedova
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

6.  Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif.

Authors:  E R Yassin; A M Abdul-Nabi; A Takeda; N R Yaseen
Journal:  Leukemia       Date:  2010-03-25       Impact factor: 11.528

7.  Combination treatment of all-trans retinoic acid (ATRA) and γ-secretase inhibitor (DAPT) cause growth inhibition and apoptosis induction in the human gastric cancer cell line.

Authors:  Elham Patrad; Ali Niapour; Faris Farassati; Mojtaba Amani
Journal:  Cytotechnology       Date:  2018-02-07       Impact factor: 2.058

8.  A phase II study of RO4929097 in metastatic colorectal cancer.

Authors:  Jonathan R Strosberg; Timothy Yeatman; Jill Weber; Domenico Coppola; Michael J Schell; Gang Han; Khaldoun Almhanna; Richard Kim; Tiffany Valone; Helen Jump; Dan Sullivan
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

9.  Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9.

Authors:  Enas R Yassin; Nayan J Sarma; Anmaar M Abdul-Nabi; James Dombrowski; Ye Han; Akiko Takeda; Nabeel R Yaseen
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

10.  Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.

Authors:  Edward Pan; Jeffrey G Supko; Thomas J Kaley; Nicholas A Butowski; Timothy Cloughesy; Jinkyu Jung; Serena Desideri; Stuart Grossman; Xiaobu Ye; Deric M Park
Journal:  J Neurooncol       Date:  2016-11-08       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.